Biotech's 2004 IPO Hopefuls Expecting Large Step-ups
Biotech companies waiting in the IPO pipeline have one thing in common: on average, they're expecting step-ups far in excess of those for companies which have already gone public this year.
Biotech companies waiting in the IPO pipeline have one thing in common: on average, they're expecting step-ups far in excess of those for companies which have already gone public this year.